UBC Perspectives from Asembia’s AXS24 Summit
Patient services are undergoing rapid changes based on regulatory requirements and evolving patient and prescriber expectations.
The Use of AI/ChatGPT in the Preparation of Aggregate Safety Reports & Signal Management Activities
At UBC, we share a vision where AI and safety writing come together to forge a safer path.
Experience the Difference with UBC’s REMS Professionals
At UBC, we are committed to our continued partnership with our customers and to providing exceptional work on behalf of our patients
EDC and PV Safety Database Integration: Practical Application and Implementation
Our PV experts discuss best practices and considerations for implementation involving PV technical, clinical, and operational stakeholders to ensure seamless compatibility.
Enhancing Patient Engagement: Insights from Access USA 2024
Read about three key areas where patient service providers are focusing to better service patients’ needs with advocates and biopharma.
Achieving Global Harmonization: PV & RMP Regulatory Compliance
UBC Pharmacovigilance experts, Helena Pedrosa and Philippe Botteron presented at DIA Europe on how to achieve global harmonization of PV & RMP regulatory compliance.
UBC Participates in Rare Disease Day® at NIH 2024
UBC joined patients, researchers, and industry leaders at this year’s Rare Disease Day at NIH to discuss advancing research, improving diagnostics, and accelerating treatments for those living with rare diseases.
The Joint Clinical Assessment Affect on European Patient Access
Find out what the new Joint Clinical Assessment from the European Union could mean for accelerating patient access to innovative medicines.
Pharmacovigilance AI Best Practices: How to Apply the EU AI Act 2023
Read into the latest PV AI Best Practices, discover how to apply the EU AI Act 2023.
Podcast: Considerations for How AI Will Impact Your Brand’s Patient Services
UBC talked to Pharmaceutical Commerce about what artificial intelligence capabilities could do to impact patient access in 2024 and beyond.
